BlossomHill Therapeutics, Inc. BLSM
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 110.74% | 17.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 74.93% | 93.01% | |||
| Operating Income | -74.93% | -93.01% | |||
| Income Before Tax | -79.39% | -100.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -79.39% | -100.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -79.39% | -100.50% | |||
| EBIT | -74.93% | -93.01% | |||
| EBITDA | -75.31% | -93.35% | |||
| EPS Basic | -58.99% | -85.45% | |||
| Normalized Basic EPS | -58.99% | -85.45% | |||
| EPS Diluted | -58.99% | -85.45% | |||
| Normalized Diluted EPS | -58.99% | -85.45% | |||
| Average Basic Shares Outstanding | 12.83% | 8.11% | |||
| Average Diluted Shares Outstanding | 12.83% | 8.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||